Actelion Pharmaceuticals Ltd: Actelion to host Conference Call / Audiocast following the US FDA approval of Opsumit (macitentan)

  Actelion Pharmaceuticals Ltd: Actelion to host Conference Call / Audiocast
  following the US FDA approval of Opsumit (macitentan) for the treatment of
                       pulmonary arterial hypertension

Actelion Pharmaceuticals Ltd / Actelion to host Conference Call / Audiocast
following the US FDA approval of Opsumit (macitentan) for the treatment of
pulmonary arterial hypertension . Processed and transmitted by Thomson Reuters
ONE. The issuer is solely responsible for the content of this announcement.

Dear member of the investment community,

Actelion Ltd will host a Conference Call / Audiocast on following the US FDA
approval of Opsumit® (macitentan) for the treatment of pulmonary arterial
hypertension today, on Monday, 21 October 2013, at 14.00 CET / 13.00 BST /
08.00 a.m. EST.

The company announced on the 18 October 2013 that the United States Food and
Drug Administration (FDA) has approved the use of the orally available
endothelin receptor antagonist Opsumit® (macitentan) 10 mg once daily for the
treatment of pulmonary arterial hypertension (PAH) to delay disease
progression.



Date/Time:

                                      
21 October 2013 14.00 hrs - 15.00 hrs   Basel (CET)
               13.00 hrs - 14.00 hrs   UK (BST)
               08.00 a.m. - 09.00 a.m. US (EST)



Conference Call Connect #:

Dial-in participants should start calling the number below 10-15 minutes
before the conference is due to start.

Dial: Europe: +41 (0)44 580 00 74
     UK:     +44 (0)203 367 94 53
              +1 866 907 59 23
     US:
              

Participant's mode:

Listen-Only with possibility to open individual lines during Q&A session.
Participants will be asked for their Name and Company.

Audiocast Access:

Audiocast participants should visit the Actelion website www.actelion.com
10-15 minutes before the conference is due to start.

Participant's mode:

Listen only



Audiocast Replay:

The archived Investor Audiocast will be available for replay through
http://www.actelion.com approximately 60 minutes after the call has ended.



For further information please contact:



Roland Haefeli
Senior Vice President, Head of Investor Relations & Public Affairs
+41 61 565 62 62
+1 646 737 49 72
http://www.actelion.com



Invitation PDF

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
HUG#1736798

--- End of Message ---

Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland

ISIN: CH0010532478;
 
Press spacebar to pause and continue. Press esc to stop.